Pembrolizumab in lung cancer: Indication of considerable added benefit

(Institute for Quality and Efficiency in Health Care) Advantages, e.g. in mortality, notably outweigh the disadvantages in some side effects in comparison with docetaxel. An added benefit over best supportive care is not proven.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news